Imeglimin is the first in a new class of oral antidiabetic agents, the glimins. Imeglimin decreases hepatic glucose production, increases muscle glucose uptake, and improves pancreatic glucose-dependent insulin secretion. The drug performed well in combination with metformin in its latest trial. Read more